Immunic to Showcase Innovations at Upcoming Investor and Scientific Conferences in February 2025
Immunic to Showcase Innovations at Upcoming Investor and Scientific Conferences in February 2025
Immunic, Inc. (Nasdaq: IMUX), a distinguished biotechnology firm focusing on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases, has outlined its participation in several prominent investor and scientific conferences throughout February 2025.
Conference Participation Schedule
1. BIO CEO & Investor Conference (February 10-11, 2025)
Immunic's CEO, Dr. Daniel Vitt, will engage in one-on-one discussions at this conference in New York City. Investors interested in scheduling a meeting can utilize the BIO Partnering™ system or reach out to Jessica Breu at [email protected].
2. Oppenheimer 35th Annual Healthcare Life Sciences Conference (February 11-12, 2025)
Dr. Vitt will also take part in a fireside chat on February 12 at 12:00 PM ET during this virtual event. The chat is expected to attract broad interest as it will address the latest developments in Immunic's drug pipeline. Interested parties can access the webcast on Immunic's
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.